NasdaqCM:ELDNBiotechs
Evaluating Eledon Pharmaceuticals (ELDN) Valuation Following Phase 2 BESTOW Results and Pipeline Progress
Eledon Pharmaceuticals (ELDN) is in the spotlight after presenting Phase 2 clinical trial results for its lead drug, tegoprubart, aimed at preventing rejection in kidney transplant patients. The data, while mixed on headline endpoints, has intensified market and medical sector curiosity about the company’s pipeline.
See our latest analysis for Eledon Pharmaceuticals.
Eledon’s share price took a dramatic hit this week, dropping nearly 50% in a single day after the Phase 2 trial update. This...